Filing Details

Accession Number:
0000911916-17-000034
Form Type:
4
Zero Holdings:
No
Publication Time:
2017-01-05 16:37:04
Reporting Period:
2017-01-05
Filing Date:
2017-01-05
Accepted Time:
2017-01-05 16:37:04
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1348649 Colucid Pharmaceuticals Inc. CLCD Pharmaceutical Preparations (2834) 203419541
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1639978 P. Thomas Mathers C/O Colucid Pharmaceuticals, Inc.
222 Third Street
Cambridge MA 02142
Chief Executive Officer Yes Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2017-01-05 3,755 $0.00 258,021 No 4 M Direct
Common Stock Disposition 2017-01-05 802 $34.25 257,219 No 4 S Direct
Common Stock Disposition 2017-01-05 200 $34.86 257,019 No 4 S Direct
Common Stock Disposition 2017-01-05 500 $35.60 256,519 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 M Direct
No 4 S Direct
No 4 S Direct
No 4 S Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Restricted Stock Units Disposition 2017-01-05 3,755 $0.00 3,755 $0.00
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
105,147 No 4 M Direct
Footnotes
  1. Each restricted stock unit ("RSU") represents a contingent right to receive one share of CoLucid Pharmaceuticals, Inc. common stock.
  2. Securities sold pursuant to a written plan intended to comply with Rule 10b5-1(c)(i) adopted by Mr. Mathers on August 19, 2016. The purpose of the plan was to sell shares of common stock in order to pay the taxesrelated to the settlement of the RSUs.
  3. Represents the sale of 802 shares in multiple transactions, ranging in price from $33.45 to $34.40 per share, resulting in a weighted average sale price of $34.2462. The reporting person will provide, upon request by the SEC staff, the Issuer or a security holder of the Issuer, full information regarding the number of shares sold at each price within the range.
  4. Represents the sale of 200 shares in multiple transactions, ranging in price from $34.50 to $35.225 per share, resulting in a weighted average sale price of $34.8625. The reporting person will provide, upon request by the SEC staff, the Issuer or a security holder of the Issuer, full information regarding the number of shares sold at each price within the range.
  5. On May 5, 2015, the reporting person received 360,508 RSUs. Those RSUs vest as follows: 50% of the RSUs vested on November 5, 2015; 12.5% of the RSUs vested on May 5, 2016; and the remaining RSUs vest in a series of 36 successive equal monthly installments upon completion of each additional month of service.